Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

154.32
+3.632.41%
Pre-market: 154.990.6700+0.43%07:03 EDT
Volume:402.54K
Turnover:61.64M
Market Cap:9.99B
PE:149.83
High:154.95
Open:152.10
Low:150.82
Close:150.69
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:0.74
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.87
PE(LYR):-75.28

Loading ...

Protagonist Therapeutics shareholders approve 2026 equity incentive plan at annual meeting

Reuters
·
Jun 19

Protagonist Therapeutics grants inducement equity awards for 18,700 shares at $112.46 strike

Reuters
·
Jun 17

Top Protagonist Therapeutics Insider Makes a Major Move With His Shares

TIPRANKS
·
Jun 12

Protagonist Therapeutics director William D. Waddill disposes of USD 969,120 in common shares

Reuters
·
Jun 12

Could New Rusfertide Data Presentations Subtly Reframe Protagonist Therapeutics' (PTGX) Core Investment Narrative?

Simply Wall St.
·
Jun 04

Protagonist Therapeutics director William D. Waddill disposes of 9,000 common shares worth $896,760

Reuters
·
Jun 02

Protagonist Therapeutics CEO Patel to speak at Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

J&J Mastered Cancer Biotech Deals on the Cheap. Can it Stay on the Cutting Edge? -- Heard on the Street -- WSJ

Dow Jones
·
May 28

Genvor names Donald Kalkofen chief financial officer

Reuters
·
May 21

Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)

TIPRANKS
·
May 14

Protagonist Therapeutics CEO Dinesh Patel disposes of USD 7.51 million common shares

Reuters
·
May 13

Protagonist Therapeutics director Bryan Giraudo disposes 59,130 shares worth $5.92 million

Reuters
·
May 12

Protagonist Therapeutics (PTGX) Receives a Buy from Citi

TIPRANKS
·
May 10

Protagonist Therapeutics Q1 Profit Challenges Trailing Loss Narrative For PTGX Investors

Simply Wall St.
·
May 07

Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs

TIPRANKS
·
May 07

Protagonist Therapeutics management to meet virtually with Clear Street

TIPRANKS
·
May 07

Protagonist Therapeutics participates in a conference call with JPMorgan

TIPRANKS
·
May 07

H.C. Wainwright Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

TIPRANKS
·
May 07

Wedbush Adjusts Price Target on Protagonist Therapeutics to $118 From $112, Maintains Outperform Rating

MT Newswires Live
·
May 06

Protagonist Therapeutics Is Maintained at Outperform by Wedbush

Dow Jones
·
May 06